THC, CBD, CBN and CBG: what science really lets us say

Cannabis produces more than a hundred phytocannabinoids. They do not share the same level of evidence or risk profile. A label full of acronyms does not guarantee a better product.

THC: the main intoxicating cannabinoid

Delta-9-THC acts in part on CB1 receptors. It can alter perception, memory, coordination and reaction time. Chronic-pain trials show small average benefits for some patients, alongside adverse effects such as dizziness, drowsiness, nausea or trouble concentrating. A higher dose is not automatically more effective.

CBD: non-intoxicating, but pharmacologically active

Cannabidiol does not produce typical THC intoxication. It can still cause drowsiness, diarrhea and drug interactions. Its effectiveness is established for certain epilepsies using a purified prescription medicine; for anxiety, sleep or pain, studied formulations and doses vary and results remain uneven.

CBN: the cannabinoid marketed for sleep

Cannabinol is often marketed as a sleep cannabinoid. A small randomized trial in adults with poor-quality sleep found some subjective changes, but adding CBD did not consistently improve results. Evidence does not yet justify presenting CBN as a proven sleep medication.

CBG: early data, not yet certainty

Cannabigerol is a non-intoxicating minor cannabinoid. A first small controlled trial in 34 healthy adults reported acute reductions in some anxiety and stress measures without subjective intoxication. It does not show that CBG treats an anxiety disorder or that a one-time result persists.

Why ratio and dose matter

A product profile is more than its featured ingredient. THC:CBD ratio, milligrams per dose, route, frequency, other medications and prior experience all change the response. A treatment journal helps compare the target effect, adverse effects and daily function instead of relying on a cultivar name.

The Coverleaf method

After clinical assessment, support focuses on a measurable starting point, gradual adjustment, a format available from an authorized medical seller and reassessment. Experience gained with more than 7,000 patients helps the team ask better questions and organize follow-up; it never replaces the practitioner's decision or individual response.